KRAS and adenoma: The conventional adenoma pathway accounts for approximately 70% of CRCs and is defined by loss of function mutation in the Wnt/beta catenin pathway regulator gene APC, typically followed by activating mutations of the KRAS oncogene, leading to a chromosomal instability (CIN) genotype of microsatellite stable CRC [1].